Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.

Choueiri TK, Albigès L, McDermott DF, Hammers HJ, Escudier B, Burotto M, Plimack ER, Porta C, George S, Powles T, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Castellano D, Grünwald V, Tomita Y, Rini BI, Jiang R, van Kooten Losio M, Lee CW, Tannir NM, Motzer RJ

Open source

DOI: 10.1016/j.annonc.2026.02.017
Published: 2026 Jul
Container: Annals of oncology : official journal of the European Society for Medical Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2026.02.017,
  title = {Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.},
  author = {Choueiri TK and Albigès L and McDermott DF and Hammers HJ and Escudier B and Burotto M and Plimack ER and Porta C and George S and Powles T and Donskov F and Atkins MB and Gurney H and Kollmannsberger CK and Grimm MO and Barrios C and Castellano D and Grünwald V and Tomita Y and Rini BI and Jiang R and van Kooten Losio M and Lee CW and Tannir NM and Motzer RJ},
  year = {2026},
  journal = {Annals of oncology : official journal of the European Society for Medical Oncology},
  doi = {10.1016/j.annonc.2026.02.017},
  url = {https://doi.org/10.1016/j.annonc.2026.02.017}
}

RIS

TY  - JOUR
TI  - Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.
AU  - Choueiri TK
AU  - Albigès L
AU  - McDermott DF
AU  - Hammers HJ
AU  - Escudier B
AU  - Burotto M
AU  - Plimack ER
AU  - Porta C
AU  - George S
AU  - Powles T
AU  - Donskov F
AU  - Atkins MB
AU  - Gurney H
AU  - Kollmannsberger CK
AU  - Grimm MO
AU  - Barrios C
AU  - Castellano D
AU  - Grünwald V
AU  - Tomita Y
AU  - Rini BI
AU  - Jiang R
AU  - van Kooten Losio M
AU  - Lee CW
AU  - Tannir NM
AU  - Motzer RJ
PY  - 2026
JO  - Annals of oncology : official journal of the European Society for Medical Oncology
DO  - 10.1016/j.annonc.2026.02.017
UR  - https://doi.org/10.1016/j.annonc.2026.02.017
ER  -

APA

TK, C., L, A., DF, M., HJ, H., B, E., M, B., ER, P., C, P., S, G., T, P., F, D., MB, A., H, G., CK, K., MO, G., C, B., D, C., V, G., Y, T., BI, R., R, J., M, V. K. L., CW, L., NM, T., & RJ, M. (2026). Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2026.02.017

Source records

pubmed · retrieved 2026-09-27T15:56:54.514Z